AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25851642 — intervention group
Group type: COMPARATOR
Intervention: Didactic instruction
Number of subjects: 31
Study 25851642 — intervention group
Group type: COMPARATOR
Intervention: Performance testing
Number of subjects: 31
Study 24072969 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle force training
Number of subjects: 55
Study 24072969 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance and muscle force training
Number of subjects: 55
Study 24072969 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered training
Number of subjects: 55
Study 24072969 — intervention group
Group type: COMPARATOR
Intervention: Guided training
Number of subjects: 55
Study 24072969 — intervention group
Group type: EXPERIMENTAL
Intervention: All training groups
Number of subjects: 55
Study 20950307 — intervention group
Group type: EXPERIMENTAL
Intervention: Conveen Optima urisheaths
Number of subjects: 61
Study 20950307 — intervention group
Group type: COMPARATOR
Intervention: Absorbent products (APs)
Number of subjects: 61
Study 19263014 — intervention group
Group type: EXPERIMENTAL
Intervention: OMM: omeprazole 20 mg twice a day, moxifloxacin 400 mg/day, metronidazole 500 mg three times a day
Number of subjects: 160
Study 19263014 — intervention group
Group type: COMPARATOR
Intervention: OBMT: omeprazole 20 mg twice a day, colloidal bismuth subcitrate 120 mg four times a day, metronidazole 500 mg three times a day, tetracycline 500 mg four times a day
Number of subjects: 160
Study 17245477 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 0
Study 17245477 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15044693 — intervention group
Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid (ATRA)
Number of subjects: 61
Study 15044693 — intervention group
Group type: EXPERIMENTAL
Intervention: Arsenic trioxide (As(2)O(3))
Number of subjects: 61
Study 15044693 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ATRA and As(2)O(3)
Number of subjects: 61
Study 11437721 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafarelin
Number of subjects: 48
Study 11437721 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate
Number of subjects: 48
Study 11437721 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 48
Study 9724825 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition program assessments and interventions during baseline
Number of subjects: 49
Study 8304833 — intervention group
Group type: EXPERIMENTAL
Intervention: rPDGF‐BB 100 micrograms/mL
Number of subjects: 41
Study 8304833 — intervention group
Group type: EXPERIMENTAL
Intervention: rPDGF‐BB 300 micrograms/mL
Number of subjects: 41
Study 8304833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 3059275 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic systemic antibiotherapy with ceftriaxone (CRO)
Number of subjects: 78
Study 3059275 — intervention group
Group type: COMPARATOR
Intervention: Non prophylactic CRO
Number of subjects: 78
Study 30535165 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-mA anodal tDCS
Number of subjects: 8
Study 30535165 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 8
Study 28750995 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching of piriformis and iliopsoas muscles
Number of subjects: 48
Study 28750995 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching of piriformis and iliopsoas muscles and Maitland's rhythmic oscillatory thoracic mobilization
Number of subjects: 48
Study 28750995 — intervention group
Group type: COMPARATOR
Intervention: Seat cushioning + Sitz bath + Phonophorosis
Number of subjects: 48
Study 26607432 — intervention group
Group type: EXPERIMENTAL
Intervention: OSTA program
Number of subjects: 320
Study 26607432 — intervention group
Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 320
Study 23462284 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (BoNT/A)
Number of subjects: 18
Study 23462284 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 18
Study 21252669 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced intensity conditioning (RIC)
Number of subjects: 0
Study 21252669 — intervention group
Group type: COMPARATOR
Intervention: Myeloablative conditioning (MAC)
Number of subjects: 0
Study 19323021 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol gum containing funoran and calcium hydrogenphosphate
Number of subjects: 7
Study 19323021 — intervention group
Group type: COMPARATOR
Intervention: Xylitol gum
Number of subjects: 7
Study 19323021 — intervention group
Group type: COMPARATOR
Intervention: Sugar gum
Number of subjects: 7
Study 19323021 — intervention group
Group type: COMPARATOR
Intervention: Gum base
Number of subjects: 7
Study 16991062 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral sequential total knee arthroplasty under one anaesthesia session
Number of subjects: 140
Study 15152279 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin (6000 IU/day intravenously)
Number of subjects: 51
Study 15152279 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (100 microg three times daily subcutaneously)
Number of subjects: 51
Study 15152279 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard medical treatment)
Number of subjects: 51
Study 15152279 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 51
Study 15152279 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 51
Study 15152279 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 51
Study 11425674 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescein dye prewarmed to body temperature
Number of subjects: 394
Study 11425674 — intervention group
Group type: COMPARATOR
Intervention: Fluorescein dye at room temperature (control group)
Number of subjects: 394
Study 9274455 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. 5-dFUR 3000 mg/m2 with L-leucovorin 25 mg/dose on days 1-5, every 3 weeks
Number of subjects: 48
Study 9274455 — intervention group
Group type: EXPERIMENTAL
Intervention: oral 5-dFUR 1200 mg/m2 for 5 days followed by 5 days off with oral L-leucovorin 25 mg/dose 2 h before 5-dFUR
Number of subjects: 48
Study 9274455 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 48
Study 9274455 — intervention group
Group type: COMPARATOR
Intervention: oral 5-dFUR
Number of subjects: 48
Study 9274455 — intervention group
Group type: COMPARATOR
Intervention: i.v. 5-dFUR
Number of subjects: 48
Study 8101695 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg daily
Number of subjects: 0
Study 8101695 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg bid
Number of subjects: 0
Study 3729450 — intervention group
Group type: EXPERIMENTAL
Intervention: LENTINAN in patients with normal protein levels
Number of subjects: 0
Study 3729450 — intervention group
Group type: COMPARATOR
Intervention: LENTINAN in patients with low protein levels
Number of subjects: 0
Study 3729450 — intervention group
Group type: EXPERIMENTAL
Intervention: OK-432 or LENTINAN in N-mice
Number of subjects: 0
Study 3729450 — intervention group
Group type: COMPARATOR
Intervention: OK-432 or LENTINAN in D-mice
Number of subjects: 0
Study 3729450 — intervention group
Group type: COMPARATOR
Intervention: Estradiol administration every 7 days
Number of subjects: 0
Study 3729450 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral oophorectomy in N-mice
Number of subjects: 0
Study 3729450 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of OK-432 or LENTINAN
Number of subjects: 0
Study 3729450 — intervention group
Group type: COMPARATOR
Intervention: D-mice
Number of subjects: 0
Study 3729450 — intervention group
Group type: COMPARATOR
Intervention: N-mice
Number of subjects: 0
Study 30406696 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM17938 (1×10^8 cfu) for 28 days
Number of subjects: 59
Study 30406696 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 28 days
Number of subjects: 59
Study 28441936 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioimpedance spectroscopy (BI) determination of normally hydrated weight to set a post-dialysis target weight that limits volume depletion
Number of subjects: 516
Study 28441936 — intervention group
Group type: COMPARATOR
Intervention: Current standard practice (control group)
Number of subjects: 516
Study 28441936 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary outcomes
Number of subjects: 516
Study 25381018 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% Carbamide Plus
Number of subjects: 33
Study 25381018 — intervention group
Group type: COMPARATOR
Intervention: 10% carbamide peroxide
Number of subjects: 33
Study 24278177 — intervention group
Group type: EXPERIMENTAL
Intervention: Formalin-inactivated EV71 vaccine candidate (EV71vac) at 5- and 10-µg doses
Number of subjects: 60
Study 21068104 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of the last disease-modifying antirheumatic drug (DMARD) after achieving DAS < 1.6 for ≥ 6 months.
Number of subjects: 508
Study 21068104 — intervention group
Group type: EXPERIMENTAL
Intervention: Restarting treatment with DMARD after DAS increased to ≥ 1.6.
Number of subjects: 508
Study 21068104 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who restarted treatment during the year of DAS increase.
Number of subjects: 508
Study 18467929 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental computerized training for visual-motor coordination
Number of subjects: 1
Study 18467929 — intervention group
Group type: COMPARATOR
Intervention: Control participants
Number of subjects: 1
Study 17080541 — intervention group
Group type: EXPERIMENTAL
Intervention: Baduanjin qigong training program for 12 weeks
Number of subjects: 87
Study 17080541 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 87
Study 12964891 — intervention group
Group type: COMPARATOR
Intervention: Cabergoline
Number of subjects: 0
Study 12964891 — intervention group
Group type: COMPARATOR
Intervention: Pramipexole
Number of subjects: 0
Study 12964891 — intervention group
Group type: COMPARATOR
Intervention: Ropinirole
Number of subjects: 0
Study 12964891 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole and Ropinirole
Number of subjects: 0
Study 12964891 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline, Pramipexole, Ropinirole
Number of subjects: 0
Study 11121628 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy (Arm I, n = 82)
Number of subjects: 159
Study 11121628 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional/accelerated‐hyperfractionated radiotherapy (Arm II, n = 77)
Number of subjects: 159
Study 11121628 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional/accelerated‐hyperfractionated radiotherapy (Arm II)
Number of subjects: 159
Study 11121628 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy (Arm I)
Number of subjects: 159
Study 9226387 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline fibers (Actisite) applied to 2 selected lesions in 9 patients (LT)
Number of subjects: 19
Study 9226387 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymeric tetracycline HCl containing fibers applied after full mouth scaling and root planing in 10 patients (FT)
Number of subjects: 19
Study 9226387 — intervention group
Group type: EXPERIMENTAL
Intervention: Full mouth scaling and root planing with 0.2% chlorhexidine rinse in 10 patients (FT)
Number of subjects: 19
Study 9226387 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group)
Number of subjects: 19
Study 8428895 — intervention group
Group type: EXPERIMENTAL
Intervention: quazepam 15 mg
Number of subjects: 65
Study 8428895 — intervention group
Group type: EXPERIMENTAL
Intervention: triazolam 0.5 mg
Number of subjects: 65
Study 8428895 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 65
Study 3304301 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine (DHE) 10 micrograms/kg body weight intravenously
Number of subjects: 10
Study 29128895 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 756
Study 29128895 — intervention group
Group type: COMPARATOR
Intervention: No tamoxifen
Number of subjects: 756
Study 28882116 — intervention group
Group type: EXPERIMENTAL
Intervention: PROMPT training package (Train the Trainers program) implemented in participating Units
Number of subjects: 12
Study 25687748 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotically assisted navigation (Hansen Sensei(®) X)
Number of subjects: 40
Study 25687748 — intervention group
Group type: COMPARATOR
Intervention: Standard navigation
Number of subjects: 40
Study 23991629 — intervention group
Group type: COMPARATOR
Intervention: CSII alone
Number of subjects: 160
Study 23991629 — intervention group
Group type: EXPERIMENTAL
Intervention: CSII with rosiglitazone
Number of subjects: 160
Study 23991629 — intervention group
Group type: EXPERIMENTAL
Intervention: CSII with metformin
Number of subjects: 160
Study 23991629 — intervention group
Group type: EXPERIMENTAL
Intervention: CSII with α-lipoic acid
Number of subjects: 160
Study 21146914 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartCode BLS System
Number of subjects: 180
Study 21146914 — intervention group
Group type: EXPERIMENTAL
Intervention: BLS Anytime
Number of subjects: 180
Study 21146914 — intervention group
Group type: COMPARATOR
Intervention: Traditional training
Number of subjects: 180
Study 18197742 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 0
Study 18197742 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 0
Study 16511428 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA prime, recombinant fowlpox virus boost vaccine (1 mg pHIS-HIV-B at weeks 0 and 4, 5 x 10^7 pfu rFPV-HIV-B at week 8)
Number of subjects: 24
Study 16511428 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 12687838 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with atrial flutter (group I)
Number of subjects: 201
Study 12687838 — intervention group
Group type: COMPARATOR
Intervention: Patients with atrial fibrillation (group II)
Number of subjects: 201
Study 12687838 — intervention group
Group type: COMPARATOR
Intervention: Comparison of group II to group I
Number of subjects: 201
Study 12846617 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-operative end tidal PCO2 of 5.99 kPa (hypercapnia)
Number of subjects: 20
Study 12846617 — intervention group
Group type: COMPARATOR
Intervention: Intra-operative end tidal PCO2 of 3.99 kPa (control)
Number of subjects: 20
Study 10474500 — intervention group
Group type: EXPERIMENTAL
Intervention: Multileaf collimator (MLC) supported by a digitizing data entry system
Number of subjects: 66
Study 10474500 — intervention group
Group type: COMPARATOR
Intervention: Conventional shielding with geometrically shaped blocks
Number of subjects: 66
Study 8768868 — intervention group
Group type: EXPERIMENTAL
Intervention: CPA‐100 (100 mg/day) + TE (100 mg/week)
Number of subjects: 15
Study 8768868 — intervention group
Group type: EXPERIMENTAL
Intervention: CPA‐50 (50 mg/day) + TE (100 mg/week)
Number of subjects: 15
Study 8768868 — intervention group
Group type: COMPARATOR
Intervention: TE (100 mg/week) alone
Number of subjects: 15
Study 8768868 — intervention group
Group type: EXPERIMENTAL
Intervention: CPA‐100 and CPA‐50 groups
Number of subjects: 15
Study 8768868 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 15
Study 1881954 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed electrical stimulation (30 minutes, twice daily, pulse frequency of 128 pps, peak amplitude of 29.2 mA) for chronic dermal ulcers.
Number of subjects: 47
Study 1881954 — intervention group
Group type: COMPARATOR
Intervention: Sham electrical stimulation (same protocol as treatment group).
Number of subjects: 47
Study 6189601 — intervention group
Group type: EXPERIMENTAL
Intervention: Peplomycin plus carbazilquinone
Number of subjects: 53
Study 6189601 — intervention group
Group type: EXPERIMENTAL
Intervention: Peplomycin plus mitomycin
Number of subjects: 53
Study 6189601 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 53
Study 6189601 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall response rate
Number of subjects: 53
Study 6189601 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse effects
Number of subjects: 53
Study 3106459 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH 1‐40 (1 microgram/Kg bw) iv at time 0
Number of subjects: 9
Study 3106459 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH 1‐40 (1 microgram/Kg bw) iv at time 0 plus TRH (6 micrograms/min) infusion between ‐30 and +120 min
Number of subjects: 9
Study 3106459 — intervention group
Group type: COMPARATOR
Intervention: TRH (6 micrograms/min) infusion between ‐30 and +120 min
Number of subjects: 9
Study 31665956 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized hemodialysis scheme (low temperature, pattern of natrium, pattern of step ultrafiltration, dialysate containing glucose)
Number of subjects: 60
Study 31665956 — intervention group
Group type: COMPARATOR
Intervention: Standard dialysis model
Number of subjects: 60
Study 31665956 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized hemodialysis scheme
Number of subjects: 60
Study 31665956 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups after dialysis
Number of subjects: 60
Study 30279333 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole milk supplementation (250 mL/day for four weeks)
Number of subjects: 62
Study 30279333 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole milk supplementation
Number of subjects: 62
Study 26689520 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritubal analgesic infiltration with 10mL of bupivacaine
Number of subjects: 105
Study 24025464 — intervention group
Group type: EXPERIMENTAL
Intervention: Caring∼Web site intervention for family caregivers of stroke patients
Number of subjects: 36
Study 22025430 — intervention group
Group type: EXPERIMENTAL
Intervention: COMPETE III CDSS intervention
Number of subjects: 1102
Study 22025430 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1102
Study 18471347 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin/metformin (50/1000 mg) fixed-dose combination tablet after a high-fat meal
Number of subjects: 23
Study 16926667 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (n = 16) participated in a supervised exercise programme for 8 months consisting of two sessions of circuit weight training and two sessions of aerobic training.
Number of subjects: 30
Study 16926667 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (n = 16)
Number of subjects: 30
Study 16926667 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (n = 16) after 3 months of detraining
Number of subjects: 30
Study 16926667 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 14)
Number of subjects: 30
Study 14693322 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin
Number of subjects: 87
Study 14693322 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 10686266 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) at 90% power of the motor threshold, stimulation frequency of 10 Hz for either 2 sec or 6 sec for 20 trains, treated for up to 20 treatment days.
Number of subjects: 40
Study 10686266 — intervention group
Group type: COMPARATOR
Intervention: Electroconvulsive therapy (ECT) performed according to standard protocols.
Number of subjects: 40
Study 9077613 — intervention group
Group type: EXPERIMENTAL
Intervention: Warmed irrigation fluid at 39 degrees C
Number of subjects: 35
Study 9077613 — intervention group
Group type: COMPARATOR
Intervention: Ambient temperature irrigation fluid
Number of subjects: 35
Study 8336746 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined out‐patient therapy program (physical exercise, dietary counseling, psychological support)
Number of subjects: 17
Study 8336746 — intervention group
Group type: COMPARATOR
Intervention: Control group (initial dietary instruction only)
Number of subjects: 17
Study 8336746 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (program and control)
Number of subjects: 17
Study 8336746 — intervention group
Group type: EXPERIMENTAL
Intervention: Program children only
Number of subjects: 17
Study 8336746 — intervention group
Group type: EXPERIMENTAL
Intervention: Program children
Number of subjects: 17
Study 3511478 — intervention group
Group type: EXPERIMENTAL
Intervention: True ultrasound (US) therapy
Number of subjects: 20
Study 3511478 — intervention group
Group type: COMPARATOR
Intervention: Sham ultrasound (US) therapy
Number of subjects: 20
Study 31865815 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal injection of botulinum toxin
Number of subjects: 20
Study 31865815 — intervention group
Group type: COMPARATOR
Intervention: Saline injection (control)
Number of subjects: 20
Study 31721257 — intervention group
Group type: EXPERIMENTAL
Intervention: PHEN/TPM‐ER (3.75 mg/23 mg-15 mg/92 mg)
Number of subjects: 22
Study 31721257 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 29648856 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (CIT)
Number of subjects: 202
Study 29648856 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 202
Study 29648856 — intervention group
Group type: EXPERIMENTAL
Intervention: CGT + Citalopram (CGT + CIT)
Number of subjects: 202
Study 29648856 — intervention group
Group type: EXPERIMENTAL
Intervention: CGT + Placebo (CGT + PBO)
Number of subjects: 202
Study 29648856 — intervention group
Group type: EXPERIMENTAL
Intervention: Working alliance
Number of subjects: 202
Study 26541641 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic® with Tisseel® fibrin glue
Number of subjects: 20
Study 26541641 — intervention group
Group type: COMPARATOR
Intervention: Harmonic® only
Number of subjects: 20
Study 26541641 — intervention group
Group type: COMPARATOR
Intervention: Electrocautery
Number of subjects: 20
Study 23294276 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 2 mg twice daily
Number of subjects: 197
Study 23294276 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice daily
Number of subjects: 197
Study 23294276 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 15 mg twice daily
Number of subjects: 197